Ajitesh Korupolu Decodes India's New-Age Real Estate Success on Ravi Kewalramani's Podcast
Hyderabad (Telangana) [India], July 16: In a candid and insightful conversation on Ravi Kewalramani's podcast, Ajitesh Korupolu, Founder and CEO of ASBL, shared a compelling analysis of the key forces that are shaping India's evolving real estate landscape. He discussed key factors influencing property values, the role of urban policies in capital appreciation, and how technology is simplifying the home buying process.
In the episode titled "15x in 5 years: India's Most Underrated Real Estate Market," the conversation began with Hyderabad's real estate trajectory. Ajitesh explained how sustained investment over the past decade led to a sharp rise in prices, especially on the city's outskirts. He outlined a tiered investment strategy, showing how capital allocations vary based on proximity to the city center. Looking ahead, he predicted market stabilization, moving into a "marathon mode" with steady appreciation and that infrastructure growth and the rise of Global Capability Centers (GCCs) will be key growth drivers for Hyderabad.
India's real estate sector is transforming rapidly, driven by demand, infrastructure, and shifting buyer expectations. Ajitesh noted that while market dynamics lead the charge, politics and policy making also play a pivotal role. From regulatory reforms to urban planning, he explained how political intent can help unlock land, ensure transparency, and incentivize affordable housing. He addressed the current entry point for investors in Hyderabad. With land prices rising, the minimum investment has increased significantly. He shared a framework for investors, highlighting how strategic decisions, particularly in peripheral areas, can yield strong returns with moderate capital. In addition, he spoke about post COVID shifts in buyer's behavior. There's a growing focus on spacious homes, wellness amenities, and trust in the developer's brand. The pandemic accelerated digital adoption, prompting developers to evolve their customer engagement models.
Ajitesh emphasized how AI is easing the journey for a buyer. From chatbots and virtual tours to predictive pricing and real time updates, technology is giving buyers more control. "Real estate is a pay first, use later model, which naturally creates anxiety," he said. "We're using technology to reduce that anxiety by offering transparency through drone videos, quality reports, and digital processes to build trust and accountability." He also advocated for a "One Nation, One License" model. Such a policy, he argued, would enable credible developers to scale across states without red tape--boosting competition, innovation, quality, and affordability for buyers.
On the regulatory front, Ajitesh discussed Floor Space Index (FSI), explaining that while higher FSI allows denser growth, a blanket approach isn't ideal. FSI regulations must align with local infrastructure, population, and the city needs to promote sustainable urban development. Finally, he called Mumbai unmatched in scale, capital, and opportunity. With its vertical growth, infrastructure, and evolving policies, Mumbai remains a testbed for bold urban development models. The podcast certainly presented the vision of a real estate leader shaping India's urban future, not just through projects, but through innovation, foresight, and a deep understanding of buyer's needs.
About ASBL:
ASBL is a prominent real estate developer based in Hyderabad, renowned for its commitment to excellence, quality, innovation, and on-time delivery. At the forefront of transforming Hyderabad's real estate landscape and with over 15 million sq. ft. of residential projects planned across key locations, ASBL continues to redefine the urban living experience. The company's flagship developments, including ASBL Broadway, ASBL Lakeside, ASBL Landmark, ASBL Spire, ASBL Spectra, ASBL Springs, and ASBL Loft, exemplify its dedication to creating vibrant and world-class communities. ASBL's forward-thinking approach ensures that each project offers not just a home, but also a lifestyle, meeting the evolving needs of modern residents and investors. For more details, visit https://asbl.in/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
an hour ago
- New Indian Express
Trump tariff move unlikely to derail Tamil Nadu's industrial ambitions: Industries Minister Rajaa
CHENNAI: Tamil Nadu is prepared to absorb the impact of new US tariffs, State Industries Minister Dr TRB Rajaa said on Thursday, after US President Donald Trump announced a 25% duty on goods imported from India, escalating trade tensions between the two countries. Speaking on the sidelines of the second edition of Passenger Vehicle Expo, Rajaa said India's most industrialised state had already laid contingency plans to shield key sectors such as manufacturing, textiles, and footwear from sudden trade shocks. 'We've seen the Covid impact, we've seen global disruptions,' he said. 'If there's one state that's resilient enough to weather this, it's Tamil Nadu.' Rajaa said he was 'unhappy' with Trump's rhetoric. 'As an Indian, and as a representative of Tamil Nadu, I found the language disturbing. But we will stand by the Union government and hope the Prime Minister and his Cabinet respond with wisdom, balancing the interests of our farmers, the primary sector, and industry.' He also warned against overinterpreting the tariff move based on a single post. 'This is diplomacy in trade between two of the world's largest economies,' he said. 'It's unfortunate the US President chose such a platform for such a major announcement. But I trust Prime Minister Narendra Modi will respond in the appropriate format.'
Time of India
2 hours ago
- Time of India
Moderna layoffs: U.S. Pharma giant announces massive job cuts, to have less than 5,000 employees, MRNA stocks sink
Moderna said on Thursday it would trim roughly 10 per cent of its global workforce and have fewer than 5,000 employees by the end of the year, as the biotech accelerates its cost-cutting efforts amid declining sales of COVID-19 vaccines. The move, announced in an internal memo by CEO Stephane Bancel, is part of the company's previous plan to cut operating expenses by about $1.5 billion by 2027. "We've made significant progress by scaling down R&D as respiratory trials conclude, renegotiating supplier agreements, and reducing manufacturing costs," Bancel said in the memo. Explore courses from Top Institutes in Please select course: Select a Course Category MCA healthcare Leadership Technology Healthcare Project Management Data Science PGDM Public Policy Product Management CXO Artificial Intelligence Degree Digital Marketing Design Thinking Finance MBA Operations Management Data Analytics others Others Data Science Management Cybersecurity Skills you'll gain: Programming Proficiency Data Handling & Analysis Cybersecurity Awareness & Skills Artificial Intelligence & Machine Learning Duration: 24 Months Vellore Institute of Technology VIT Master of Computer Applications Starts on Aug 14, 2024 Get Details Moderna had said earlier this year it expects operating costs to be between $4.7 billion and $5 billion for 2027. The Cambridge, Massachusetts-based biotech has been banking on revenue from newer mRNA shots, including its experimental COVID-flu combination vaccine, to make up for falling sales of its COVID-19 shot and less-than-expected uptake of its respiratory syncytial virus vaccine. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Calcutta: 1 Trick to Reduce Belly Fat? Home Fitness Hack Shop Now Undo Moderna MRNA Stocks But investor concerns about the prospects of new shots and the changes in vaccine policy under U.S. Health Secretary and vaccine skeptic Robert F. Kennedy Jr. have led to a more than 20 per cent decline in Moderna's shares this year. Live Events The stock, which has lost more than 90 per cent of its value since the pandemic-era highs, was trading about 4 per cent down on Thursday. Moderna had said in May it did not expect regulatory approval for its combination shot until 2026, since the U.S. Food and Drug Administration asked for late-stage data showing the vaccine's efficacy against the flu. The company had previously hoped to launch the vaccine for the autumn respiratory disease season in 2025 or 2026. Bancel in the memo reiterated the company's target to have eight more approvals for its products in the next three years. FAQs Q1. Is Moderna laying off workforce? A1. Moderna said on Thursday it would trim roughly 10 per cent of its global workforce. Q2. What are Moderna's operating costs? A2. Moderna had said earlier this year it expects operating costs to be between $4.7 billion and $5 billion for 2027.
Time of India
2 hours ago
- Time of India
Moderna plans to lay off 10% of workforce to cut costs
Moderna said on Thursday it would trim roughly 10% of its global workforce and have fewer than 5,000 employees by the end of the year, as the biotech accelerates its cost-cutting efforts amid declining sales of COVID-19 vaccines. The move, announced in an internal memo by CEO Stephane Bancel , is part of the company's previous plan to cut operating expenses by about $1.5 billion by 2027. Explore courses from Top Institutes in Please select course: Select a Course Category Operations Management Finance MCA Data Science Healthcare Public Policy Digital Marketing CXO Project Management PGDM Technology Artificial Intelligence Product Management healthcare Degree MBA Data Science others Management Leadership Data Analytics Cybersecurity Others Design Thinking Skills you'll gain: Quality Management & Lean Six Sigma Analytical Tools Supply Chain Management & Strategies Service Operations Management Duration: 10 Months IIM Lucknow IIML Executive Programme in Strategic Operations Management & Supply Chain Analytics Starts on Jan 27, 2024 Get Details "We've made significant progress by scaling down R&D as respiratory trials conclude, renegotiating supplier agreements, and reducing manufacturing costs," Bancel said in the memo. Moderna had said earlier this year it expects operating costs to be between $4.7 billion and $5 billion for 2027. The Cambridge, Massachusetts-based biotech has been banking on revenue from newer mRNA shots, including its experimental COVID-flu combination vaccine, to make up for falling sales of its COVID-19 shot and less-than-expected uptake of its respiratory syncytial virus vaccine. Live Events But investor concerns about the prospects of new shots and the changes in vaccine policy under U.S. Health Secretary and vaccine skeptic Robert F. Kennedy Jr. have led to a more than 20% decline in Moderna's shares this year. The stock, which has lost more than 90% of its value since the pandemic-era highs, was trading about 4% down on Thursday. Moderna had said in May it did not expect regulatory approval for its combination shot until 2026, since the U.S. Food and Drug Administration asked for late-stage data showing the vaccine's efficacy against the flu. The company had previously hoped to launch the vaccine for the autumn respiratory disease season in 2025 or 2026. Bancel in the memo reiterated the company's target to have eight more approvals for its products in the next three years.
